NovaMedica to market Ferring's innovative GI products in Russia

Privately-held Switzerland-headquartered Ferring Pharmaceuticals has signed an agreement that gives Russian drugmaker NovaMedica the rights for commercialization of a range of Ferring’s line of innovative gastroenterological prescription drug products for the treatment of inflammatory bowel disease (IBD) in the Russian market.

The product line includes established and soon-to-launch treatments for inflammatory bowel diseases: ulcerative colitis, Crohn's disease and bleeding from esophageal varices. Employees of marketing and sales departments, medical advisors and representatives of NovaMedica will market and support the products in the Russian market. Finacial terms of the accord were not disclosed.

“The agreement with Ferring opens up broad prospects for the development of products for the treatment of gastroenterological diseases, which are one of the most widely spread and significant medical problems in Russia. Through this collaboration, we will be able to offer Russian specialists and patients new solutions for treatment using effective medicines,” noted Fabrice Egros, the chief operating officer of NovaMedica.